TW202602484A - 針對糖尿病之ｓＨＢ－ＥＧＦ強化治療 - Google Patents

針對糖尿病之ｓＨＢ－ＥＧＦ強化治療

Info

Publication number
TW202602484A
TW202602484A TW114112661A TW114112661A TW202602484A TW 202602484 A TW202602484 A TW 202602484A TW 114112661 A TW114112661 A TW 114112661A TW 114112661 A TW114112661 A TW 114112661A TW 202602484 A TW202602484 A TW 202602484A
Authority
TW
Taiwan
Prior art keywords
egf
ecd
nucleic acid
aav
diabetes
Prior art date
Application number
TW114112661A
Other languages
English (en)
Chinese (zh)
Inventor
小戝健一郎
松田恵理子
Original Assignee
國立大學法人鹿兒島大學
日商瑟弗生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人鹿兒島大學, 日商瑟弗生物製藥股份有限公司 filed Critical 國立大學法人鹿兒島大學
Publication of TW202602484A publication Critical patent/TW202602484A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW114112661A 2024-04-02 2025-04-01 針對糖尿病之ｓＨＢ－ＥＧＦ強化治療 TW202602484A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024-059835 2024-04-02
JP2024059835 2024-04-02

Publications (1)

Publication Number Publication Date
TW202602484A true TW202602484A (zh) 2026-01-16

Family

ID=97267051

Family Applications (1)

Application Number Title Priority Date Filing Date
TW114112661A TW202602484A (zh) 2024-04-02 2025-04-01 針對糖尿病之ｓＨＢ－ＥＧＦ強化治療

Country Status (3)

Country Link
JP (1) JPWO2025211357A1 (https=)
TW (1) TW202602484A (https=)
WO (1) WO2025211357A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1949907B1 (en) * 2005-09-28 2014-07-02 Kagoshima University Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes
JP2007223939A (ja) * 2006-02-22 2007-09-06 Kobe Univ エネルギー代謝促進因子としてのｈｂ−ｅｇｆの使用
JPWO2020158690A1 (ja) * 2019-01-28 2021-12-16 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
AU2022230492A1 (en) * 2021-03-03 2023-10-19 Kagoshima University Hb-egf gene therapy for diabetes

Also Published As

Publication number Publication date
JPWO2025211357A1 (https=) 2025-10-09
WO2025211357A1 (ja) 2025-10-09

Similar Documents

Publication Publication Date Title
McMahon et al. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle
Zaiss et al. Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response
JP2017504589A (ja) 避妊および卵巣予備能の保存のためのミュラー管抑制物質（ｍｉｓ）タンパク質の使用
CN113564187B (zh) 基于aav的抗血管生成基因递送系统及其用途
Su et al. Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics
KR20220010500A (ko) 난소암 치료용 rna
He et al. Rectifying the crosstalk between the skeletal and immune systems Improves osteoporosis treatment by core–shell nanocapsules
CN114933657A (zh) 神经生长因子突变体重组蛋白及其应用
WO2021042944A1 (zh) 肌肉靶向的微环dna基因治疗
CN113480615B (zh) 高视网膜亲和性的新型腺相关病毒衣壳蛋白及其应用
CN113563430B (zh) 用于治疗眼部疾病的基因递送系统及其应用
Piccolo et al. SR-A and SREC-I binding peptides increase HDAd-mediated liver transduction
CN117321212A (zh) 用于治疗法布里病的组合物和方法
CN113584043A (zh) 用于治疗视网膜疾病和癌症的转基因表达盒
TW202602484A (zh) 針對糖尿病之ｓＨＢ－ＥＧＦ強化治療
WO2020096046A1 (ja) 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
US20240173381A1 (en) Hb-egf gene therapy for diabetes
JP2022512903A (ja) Ａｄ－ＲＥＩＣ／Ｄｋｋ－３とチェックポイント阻害剤とを用いた胸部がんの治療のための併用療法
RU2853169C2 (ru) Генотерапия с использованием hb-egf для лечения диабета
US20250002998A1 (en) Urine pcr assay and use thereof to diagnose and stage feline chronic kidney disease
US20250346900A1 (en) Pharmaceutical composition for treating cancer comprising foxm1 mutant or foxm1 shrna
JP5299922B2 (ja) Ｈｂ−ｅｇｆ結合性タンパク質複合体
CN119039431B (zh) anti-PcrV单克隆抗体及其编码核酸与应用
US20230310659A1 (en) Ankyrin-rich btb/poz domain-containing protein-2 (abtb2) for suppressing pancreatic cancer growth
WO2025249511A1 (ja) メッセンジャーｒｎａを腫瘍組織に導入するために用いられる組成物およびがん治療用医薬